TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FEXINIDAZOLE

FEXINIDAZOLE Cytochrome P450 1A2 Inhibitors
Approved 2021-07-16
1
Indication
--
Phase 3 Trials
1
Priority Reviews
4
Years on Market

Details

Status
Prescription
First Approved
2021-07-16
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: FEXINIDAZOLE

FEXINIDAZOLE Approval History

Loading approval history...

What FEXINIDAZOLE Treats

1 indications

FEXINIDAZOLE is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Human African Trypanosomiasis
Source: FDA Label
šŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
šŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FEXINIDAZOLE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Fexinidazole Tablets is a nitroimidazole antimicrobial, indicated for the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of Use Due to the dec...

FEXINIDAZOLE Patents & Exclusivity

Exclusivity: Jul 2028

Exclusivity

NCE Until Jul 2026
ODE-359 Until Jul 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.